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ABSTRACT 
 
Osteocytes are the most abundant cell type in bone. Although our understanding of 
the function of osteocytes has progressed over the last decade, these cells remain the least 
understood cell in bone. Osteocytes are considered to be orchestrators of bone remodeling, 
mineral homeostasis, and hematopoiesis. The sympathetic nervous system (SNS) regulates 
almost every system in the body including bone. It is known that SNS suppresses bone 
formation but the mechanism is still not fully elucidated. Beta 2 adrenergic receptor 
(b2AR) is a G-protein coupled receptor that, upon binding to norepinephrine,  activates the 
stimulatory subunit of the heterotrimeric G protein (Gαs) and the enzyme adenylate 
cyclase. The function of b2AR in osteocytes has not been studied. Therefore, the goal of 
this study is to delineate the role of b2AR signaling in osteocytes.  
To investigate that, an osteocyte-like cell line (Ocy454) was used. Ocy454 cells 
were treated with three different agents: norepinephrine (NE), isoproterenol (ISO), and 
butoxamine. Knock down of b2AR was achieved by using short hairpin RNA. 
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Consequently, treatment with norepinephrine (NE) was done as well as fluid flow shear 
stress (FFSS) experiment.  
Taken together, this study shows that osteocytes do express b2AR and that b1AR 
and b2AR are almost equally expressed in osteocytes. Secondly, we have demonstrated 
that upon treatment of Ocy454 with NE and isoproterenol, there is a significant 
upregulation of Rankl, whereas Sost is not significantly regulated. Lastly, preliminary data 
suggest that b2AR might be involved in osteocyte’s mechanosensation. 
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INTRODUCTION 
 
Bone as an organ 
It is well known that the bone constitutes the largest part of the connective tissue in 
the body. It serves several functions, including providing support for the body, protecting 
vital organs, supplying sites for muscles attachment, and presents a reservoir for ions like 
calcium, magnesium and phosphate as well as preserving these ions homeostasis in the 
blood (Aarden, Burger et al. 1994). Anatomically, the skeleton consists of cartilaginous 
joints, the calcified cartilage in the growth plate, cortical and cancellous bone components 
as well as the bone marrow (Rosen 2013). Histologically, bone consists of various types of 
cells and calcified extracellular matrix. The extracellular matrix is made up of organic and 
inorganic compartments. The organic compartment is formed by collagen and non-
collagenous proteins which includes osteocalcin, osteopontin, osteonectin, bone 
morphogenic proteins (BMPs) and bone sialoprotein II. On the other hand, the inorganic 
compartment composed of calcium, phosphate, sodium, and magnesium among other types 
of minerals.   There are three main types of bone cells: osteoblast which is the bone forming 
cells, osteoclast which is the bone resorbing cells and osteocyte which makes up the main 
bulk of the bone cells (Aarden, Burger et al. 1994, Schaffler, Cheung et al. 2014). 
 
Osteocytes: origin and differentiation  
Our understanding of the role of osteocytes in bone has expanded exponentially 
over the last decade due to the huge technological advances in cellular and molecular 
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biology. The thought that osteocytes are just a passive component that constitutes the major 
part of bone mass has long been abandoned. The osteocyte now is recognized as a 
mechanosensory cell and an important regulator of bone metabolism through controlling 
both osteoblast and osteoclast activities. Moreover, osteocytes play an integral part in 
mineral homeostasis, hematopoiesis and fat metabolism (Divieti Pajevic 2013). This 
introduction will discuss the osteocyte’s origin, their functions and the regulators that 
govern osteocyte’s role in bone and the effect of the sympathetic nervous system on bone. 
Osteocytes are the fully differentiated osteoblasts that during the process of bone 
formation become entrapped in both mineralized and non-mineralized matrix (osteoid) 
(Divieti Pajevic 2013, Schaffler, Cheung et al. 2014). Early studies delineated two stages 
of osteocytes; an early stage (young osteocytes) which is described as small residing cells 
in the osteoid that do not express alkaline phosphatase and a late stage (mature osteocytes) 
which is characterized by larger cells deeply engulfed by mineralized matrix and 
expressing alkaline phosphatase (Rutishauser and Majno 1951). Later studies added an 
intermediate stage according to the cell’s differentiation and its gene expression. 
Osteocytes are now categorized as “osteoid”, “mineralizing”, and lastly mature osteocytes 
(Bonewald 2011).   
Although osteocytes comprise about 95% of bone cells (Schaffler, Cheung et al. 
2014), they were the least studied cells compared to the other bone cells type, namely 
osteoblasts and osteoclasts. One of the major differences between osteocytes and their 
precursor, osteoblast, is their cell shape. In the differentiation process from an osteoblast 
to an osteocyte, the cell transforms from a cuboidal cell to a dendritic one with small cell 
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body and long slender processes which connect the osteocyte with its neighboring cells 
(Palumbo 1986, Palumbo, Palazzini et al. 1990). This change in shape will necessitate a 
change in function since the cell gradually loses some cell organelles and its ability to 
secrete extracellular matrix (Aarden, Burger et al. 1994). Several studies have 
demonstrated that osteocyte differentiation is accompanied by the progressive reduction of 
the expression of early bone markers such as bone sialoprotein, collagen type I, alkaline 
phosphatase (ALP), osteocalcin and Runx2, the maintenance of some such as osteopontin 
and E11/gp38 antigen, and the appearance of new; namely dentin matrix protein 1 (Dmp1), 
CD44, matrix extracellular phosphoglycoprotein (Memp), phosphate-regulating gene with 
homologies to endopeptidases on the X chromosome (Phex), sclerostin and fibroblast 
growth factor 23 (Fgf23) (Poole, van Bezooijen et al. 2005, Franz-Odendaal, Hall et al. 
2006).    
 
Osteocyte as a mechanosensor 
The interest in understanding the role of osteocytes has become apparent in the last 
decade. Growing evidences have demonstrated that osteocytes are the mechanosensors of 
bone and regulate both osteoblast and osteoclast activity in response to mechanical stimuli 
(Robling, Niziolek et al. 2008, Nakashima, Hayashi et al. 2011, Spatz, Wein et al. 2015). 
In one of the most important studies, Tatsumi et al. demonstrated that osteocyte ablation 
results in a resistance to disuse-induced bone loss which proved the crucial role of 
osteocytes as a mechanosensor (Tatsumi, Ishii et al. 2007). Having stated that, the 
mechanisms by which osteocytes control this process is not well understood particularly 
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because visualizing cells during mechanical loading in their environment is challenging 
(Duffy and Jacobs 2015). In recent years, multiple theories were proposed by investigators 
to explain how the osteocytes recognize and respond to mechanical forces, including 
substrate deformation, hydrostatic pressure changes and fluid shear (Schaffler, Cheung et 
al. 2014). The leading theory, supported by both in vivo and some in vitro studies, is that 
the mechanical loading induces fluid flow in the lacunar– canalicular system (LCS) and 
therefore the osteocytes can recognize and respond to loading by regulating bone formation 
and resorption (You, Yellowley et al. 2000). It has been suggested that both the 
compression induced by loading and the extravascular pressure drive fluid flow (Divieti 
Pajevic 2013). Essential stimuli of mechanical loading which move fluid in the LCS are 
muscular and physical activities (Wang, Ciani et al. 2004). Osteocytes respond to loading 
by releasing prostaglandin E2 and nitric oxide as well as by regulating the expression of 
several genes like Dmp1, Memp, Phex and Sost (Gluhak-Heinrich, Ye et al. 2003, Harris, 
Gluhak-Heinrich et al. 2007). Rubin, J et al showed that multiple signaling systems are 
involved in the sensation and responses to fluid flow (Rubin, Rubin et al. 2006). One 
mechanism is through the primary cilia; an immotile antenna-like organelle which is 
associated with releasing prostaglandin E2 (PGE2) which is a regulator of bone metabolism 
in response to fluid flow and can sense fluid flow as small as 0.03 Pa  (Malone, Anderson 
et al. 2007). Forces generated by flow are directly dependent on fluid flow rates while the 
quantity of fluid stress vary greatly depending on the diameter of the canalicular space; the 
narrower the canaliculi the higher the fluid shear stress and vise versa (You, Weinbaum et 
al. 2004). 
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Osteocytes as a regulator 
 Osteocytes connect with each other and with osteoblasts and other bone cells either 
directly by gap junction or indirectly (extracellular paracrine) through secreted molecules 
(Schaffler, Cheung et al. 2014). Thereby, the osteocytes exert their effect on the 
neighboring cells and manage the modeling – remodeling process efficiently. One of the 
major effects of osteocytes on osteoblasts is through the inhibitor protein sclerostin (Poole, 
van Bezooijen et al. 2005, Spatz, Wein et al. 2015). Sclerostin, the product of the Sost gene, 
inhibits bone formation both in vitro and in vivo by directly reducing proliferation and 
differentiation of osteoblasts via inhibiting the canonical Wnt signaling pathway 
(Semenov, Tamai et al. 2005, Li, Sarosi et al. 2006, Holdsworth, Slocombe et al. 2012). 
Activation of the Wnt/b-catenin pathway occurs upon binding of Wnt ligands to a dual 
receptor complex including one of the seven transmembrane receptors of the frizzled 
family together with a low-density lipoprotein receptor– related protein 5 or 6 co-receptor 
(LRP5/6) (Glass and Karsenty 2006, Krishnan, Bryant et al. 2006). As a consequence, b-
catenin then accumulates in the cytoplasm and translocated into the nucleus to initiate the 
expression of osteoblast-specific genes (Gumbiner 1998, Wodarz and Nusse 1998, Bilic, 
Huang et al. 2007). Sclerostin is an antagonist to this pathway and by binding to LRP5 and 
LRP6 it inhibits bone formation (Li, Zhang et al. 2005). It has been shown that sclerostin 
expression is affected by mechanical loading. Increased loading leads to suppression in 
sclerostin level which is associated with increased bone formation (Robling, Bellido et al. 
2006, Robling, Niziolek et al. 2008). Contrary, unloading induces osteocytic secretion of 
sclerostin and inhibits bone formation (Gaudio, Pennisi et al. 2010, Moustafa, Sugiyama et 
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al. 2012, Spatz, Fields et al. 2012). Furthermore, research showed that Sost knock-out mice 
are resistant to disuse induced bone loss (Lin, Jiang et al. 2009). 
Osteocytes also produce dickkopf-1 (DKK-1), another inhibitor of the Wnt 
signaling pathway that binds LRP4 (Leupin, Piters et al. 2011) and LRP5/6 co-receptors to 
inhibit canonical Wnt signaling and their downstream effects (Brunkow, Gardner et al. 
2001). All these findings prove that osteocytes are not only key regulators of bone 
remodeling during mechanical loading, but also during unloading like paralysis, prolonged 
bed resting or space flights (Divieti Pajevic 2013).  
Osteocytes also regulate bone resorption as well as formation. Frost (Frost 1987) 
proposed that osteocytes are the mechanostat of bone, referring to their role in driving 
skeletal adaptation to mechanical forces. Generally, bone adapts its form to mechanical 
demands through a mechanism known as bone modeling. During modeling, osteoblasts 
and osteoclasts act on different surfaces of the skeleton such as the bone undergoes 
reshaping to adapt to different loading situations. On the other hand, bone remodeling is 
the continuous resorption and formation of the skeleton to preserve functional integrity. 
According to Frost, the mechanostat distinguishes between bone modeling (shape change) 
and remodeling (replacement only). This process is evident in professional athletes were 
the high load applied to the skeleton results in stronger and bigger bones and the opposite 
is true among astronauts. Moreover, osteocytes are the main source of receptor activation 
of nuclear factor-kB ligand (Rankl) which is an integral pro-resorptive signal needed to 
trigger the differentiation of osteoclast (Nakashima, Hayashi et al. 2011, Xiong, Onal et al. 
2011). A study reported that deletion of osteocyte Rankl resulted in a severe osteopetrotic 
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phenotype (Nakashima, Hayashi et al. 2011). Also Xiong et al. demonstrated that the bone 
mineral density (BMD) of osteocyte-specific Rankl-deficient mouse bones were 
increasingly higher than those of the wild- type controls up to 6 months of age (Xiong, 
Onal et al. 2011).  These observations indicate the importance of Rankl production by 
osteocytes in the modeling and remodeling processes of growing bone. 
 
In vitro osteocytes 
To facilitate studying the osteocytes in the lab, osteocytic-like cells were developed. 
The first osteocytes-like cells were developed by the Bonewald’s group, MLO-Y4 and 
MLO-A5 and are the most utilized cells in osteocyte cell line studies (Kato, Windle et al. 
1997, Kato, Boskey et al. 2001). MLO-Y4 cells express an osteocytic phenotype including 
low Alp, high osteocalcin, E11 and connexin 43 expression. On the other hand, they 
proliferate which is not a feature of osteocytes, they do not mineralize or express Sost 
(Kalajzic, Matthews et al. 2013). Another osteocyte-like cell is IDG-SW3 which is isolated 
from mice expressing the Dmp1-GFP reporter transgene and a conditionally immortalizing, 
temperature sensitive SV40 TAg (Woo, Rosser et al. 2011). IDG-SW3 shows progression 
from a late osteoblastic phenotype to a mature osteocytic phenotype. Also, it shows 
expression of osteocyte marker genes like Dmp1, Memp, Sost and Fgf23 (Woo, Rosser et 
al. 2011). Nonetheless, and as mentioned before, the IDG-SW3 cell line has a combination 
of osteoblast and osteocyte phenotypes at various differentiation stages which means that 
studies which require pure osteocytes have to isolate the osteocytes from the rest cells prior 
to using the IDG-SW3 (Kalajzic, Matthews et al. 2013). The most novel osteocyte-like cell 
8 
line is Ocy454. Ocy454 cells were also isolated from the long bone of 4-week-old Dmp1-
GFP and SV40 TAg double transgenic mice (Spatz, Wein et al. 2015). Unlike MLO-Y4 
and IDG-SW3, Ocy454 has the benefit of rapid, high expression of Sost/Sclerostin 
matching the in vivo osteocytes and these cells are able to respond to cytokine (PGE2), 
hormonal (PTH) and mechanical stimuli (Fulzele, Krause et al. 2013, Spatz, Wein et al. 
2015).  
 
Role of the sympathetic nervous system and adrenergic receptors in bone 
The sympathetic nervous system (SNS) regulates almost every organ in the body 
including bone. Catecholamines activate the b-adrenergic receptors (b1AR, b2AR and 
b3AR) which are expressed selectively in all different body tissues. For instance, b1AR 
are present primarily in cardiac tissue, b2AR are found in osteoblast and white adipose 
tissue, while b3AR are expressed mainly in brown adipose tissue (Motyl and Rosen 2012). 
Several histological studies reported that both periosteum and bone show an abundant 
number of sensory and sympathetic nerve fibers (Serre, Farlay et al. 1999). These fibers 
act as a receiver for the leptin dependent central regulation of bone turnover. Leptin plays 
an inductive role on neural fibers in the ventromedial hypothalamus, which leads to 
activation of the intraosseous sympathetic fibers. The sympathetic fibers in turn release 
norepinephrine (NE) that binds to the adrenergic receptors expressed on osteoblast causing 
an inhibitory effect on bone formation as well as increasing osteoblast’s production of 
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Receptor Activator of NF-kB Ligand (Rankl) which may activate osteoclasts and reduce 
bone mass (Takeda, Elefteriou et al. 2002, Elefteriou, Ahn et al. 2005).  
The b2AR is a G-protein coupled receptor (GPCR) (Veldhuis-Vlug, Oei et al. 
2015). GPCRs are membrane receptors that mediate most of physiological responses to 
hormones, neurotransmitters and environmental stimulants. GPCRs are characterized by 
the presence of seven membrane-spanning α-helical segments separated by alternating 
intracellular and extracellular loop regions (Rosenbaum, Rasmussen et al. 2009). Binding 
of epinephrine and norepinephrine to the b2AR leads to activation of the stimulatory 
subunit of the heterotrimeric G protein (Gαs) and the enzyme adenylate cyclase with 
generation of cyclic adenosine monophosphate (cAMP) (Rosenbaum, Rasmussen et al. 
2009, Veldhuis-Vlug, Oei et al. 2015). This effect has been proven by different studies 
which reported a dose-dependent increase of cAMP in reaction to b-adrenergic agonist 
isoproterenol and converse effect with non-selective b-adrenergic blocker propranolol in 
osteoblast cultures (Majeska, Minkowitz et al. 1992, Elefteriou, Ahn et al. 2005). Ligand 
binding also leads to phosphorylation of GPCR kinases which promotes down regulation 
of the receptor (Rosenbaum, Rasmussen et al. 2009). 
The role of b2AR in osteoblasts has been previously investigated and several 
studies have shown that b2AR plays a role in bone metabolism in rodents. Mice with a 
specific osteoblast b2AR knockout showed a decrease in bone resorption and increase in 
bone mineral density (Bonnet, Benhamou et al. 2005, Elefteriou, Ahn et al. 2005, 
Kajimura, Hinoi et al. 2011, Kondo and Togari 2011). Treatment of these animals with 
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beta-blockers such as propranolol or metoprolol increases bone mass by suppressing bone 
resorption and enhancing bone formation (Levasseur, Dargent-Molina et al. 2005, Wiens, 
Etminan et al. 2006). Bonnet et al. reported an enhanced bone formation indices after 
treatment with low dose propranolol in ovariectomized rats (Bonnet, Laroche et al. 2006). 
Also, it has been reported that low dose propranolol enhances bone formation rate  (BFR) 
in mildly stressed rats by 40% (Yirmiya, Goshen et al. 2006). On the contrary, several 
studies reported no effect of these medications on bone turnover markers suggesting that 
the effects of b2AR in bone might be more complex (Reid, Lucas et al. 2005, Bonnet, 
Pierroz et al. 2008).  In addition, when b2AR is stimulated in wild type mice by injection 
with beta-agonists such as isoproterenol, there is a bone loss due to suppression of bone 
formation and enhancement of bone resorption (Nagao, Feinstein et al. 2011). Beside the 
effect of adrenergic receptors on osteoblasts, it has been suggested that there is an indirect 
effect on osteoclasts as well. A study has shown that b-adrenergic stimulation indirectly 
influences osteoclastogenesis by increasing the production of Rankl in T cells (Elenkov, 
Wilder et al. 2000, Elefteriou, Ahn et al. 2005). Furthermore, treating mice and rats with 
nonselective  b-adrenergic receptor agonist isoproterenol or with selective b2 adrenergic 
receptor agonist clenbuterol or salbutamol had an osteoclastogenic effect as shown by bone 
loss and increased osteoclast formation (Takeda, Elefteriou et al. 2002, Bonnet, Benhamou 
et al. 2005).  
Recent advances in genome engineering technologies have allowed to manipulate 
gene expression, both in-vivo and in-vitro. This technological advance in tools and methods 
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improved our understanding of gene functions in the cell. There are various techniques to 
influence gene expression in mammalian cells. Transcription can be reduced by RNA 
interference (RNAi) or genes can be silenced by Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR/Cas9) technique. RNAi achieves the gene reduction by a 
specific sequence degradation of host mRNA through introducing a double-stranded RNA 
(dsRNA) identical to the target sequence into the cell’s cytoplasm. Short hairpin RNA 
(shRNA) is one example of RNAi approaches to knock down a specific gene in the cell. 
shRNA can be introduced into the cell as a plasmid vector encoding shRNAs transcribed 
by RNA pol III or modified pol II promoters. These vectors also can be transfected via 
viral particles (e.g. adenovirus or lentivirus). The basic structure of shRNA consists of the 
sense and antisense sequences (each 19-21 base pair) linked by 4-11 nucleotide forming a 
hairpin (Moore, Guthrie et al. 2010). After transcription, the shRNA sequence is introduced 
to the cytosol where it is identified by an endoribonuclease enzyme (Dicer) which 
processes the shRNA into a siRNA. This endogenously derived siRNA binds to the target 
mRNA and is integrated into the RNA-induced silencing complex (RISC) for target-
specific mRNA degradation and thereby knocking down the gene expression (Kutter and 
Svoboda 2008, Moore, Guthrie et al. 2010). 
Another powerful tool to edit genes is CRISPR/Cas9, a recently discovered  
genome editing method developed on the bacterial adaptive immune systems known as 
clustered regularly interspaced short palindromic repeats against invading viruses and 
plasmids (Hsu, Lander et al. 2014). CRISPR-Cas system utilizes both proteins and short 
RNAs to target specific DNA sequences for cleavage. Following invasion of the cell, 
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bacteria use CRISPR to recall the invading organism DNA sequence and therefore design 
a segment of RNA that binds to the invader DNA. This bind will be recognized by the 
CRISPR-associated Cas enzymes (e.g. Cas9) and cuts the invader DNA which leads to the 
invader destruction and host protection (Makarova, Haft et al. 2011, Hsu, Lander et al. 
2014). Same technique is now used in gene editing by synthesizing a short RNA (20 bases) 
called guided RNA (gRNA) which binds to the targeted DNA allowing the associated Cas 
enzyme to cut the DNA and eliminate the targeted gene. 
In spite of the fact that several studies have investigated the interaction between the 
sympathetic nervous system and bone, the exact mechanism of this interaction is not well 
understood. Moreover, the effect of SNS and the role of b2AR in osteocytes have not been 
studied. The aim of this study is to assess the role of b2AR in Ocy454 osteocytic cells. 
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MATERIALS AND METHODS 
 
Ocy454 cell line 
Ocy454 is an osteocytic-cell line isolated from the long bone of 4-week-old double 
transgenic mice expressing GFP under the control of dentin matrix protein 1 (8-kb DMP1-
GFP) and the temperature sensitive SV40 large T antigen, as previously reported. Cells 
were routinely maintained in non-collagen-coated flasks (Corning Biocoat; Corning, 
Corning, NY, USA) in a-minimum essential medium (Gibco) that contained 10% heat-
inactivated fetal bovine serum (FBS; Gibco) and 1% antibiotic antimycotic (Thermo Fisher 
Scientific) at the permissive temperature (33°C) until confluence (2-3 days) then moved to 
semi permissive temperature at (37°C) for further differentiation (10-12 days) and the 
medium was changed twice a week. For all experiments, cells were plated at 1x105 cells/ml 
and allowed to proliferate at a permissive temperature (33°C) and then moved to a semi 
permissive temperature at (37°C) and cultured for the indicated times to induce 
differentiation.  
 
Lentivirus infection 
Ocy454 cells were plated at 1 x105 cells/ml on a 12-well plate. After one day,  cells 
were infected with 100 µl of 5 independent lentiviral shRNAs targeting b2AR and 2 
independent lentiviral shRNA targeting Green fluorescent protein (GFP) as a control  
(lentiviral particles were purchased from Broad Institute) (Table 1) in the presence of 
10µg/ml polybrene. Medium was changed 1 day after infection and Puromycin selection 
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(5 µg/ml) was started at this time. After that cells were treated with the antibiotic for 14 
days. 
 
Lentiviral short hairpin RNA 
The shRNAs were prepared in our laboratory. For short hairpin RNA (shRNA), 
lentiviruses were produced in HEK293T cells in a pLKO.1-puro backbone, a gift from B. 
Weinberg (Addgene). Viral packaging was performed using standard protocols 
(https://portals.broadinstitute.org/gpp/public/resources/protocols). In summary, HEK293T 
cells were plated at 2.2 x 105 cells/ml and transfected the next day with shRNA-expressing 
plasmid along with psPAX2 and pMD2.G. Medium was changed the next day and collected 
48 hours later. 
 
 
shRNA Targeted sequence 
GFP 5’-CTACGGCAAGCTGACCCTGAA -3’ 
GFP 5’-ACAACAGCCACAACGTCTATA -3’ 
b2AR 5’-GTGCCAAATCAATAGAAGAAA -3’ 
b2AR 5’-CGGCTTATCATCAGAAAGGTA -3’ 
b2AR 5’-ACTTGTTGAAAGTGGGCATTA -3’ 
b2AR 5’-CCTCATCGAATTCGATACCAA-3’ 
b2AR 5’-GACTACTTGAAGGACCGGAAA-3’ 
Table 1. shRNA targeted sequences  
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Fluid flow shear stress (FFSS) 
For FFSS experiment, cells were plated at 1 x105 cells/ml on two 6-well plate. Each 
plate contains two cell groups: the first group is shRNA-GFP (control) and the other group 
is shRNA-b2ARKD (test), three wells for each group. Cells were plated for 3-4 days at the 
permissive temperature (33°C) and then moved to semi permissive temperature at (37°C) 
for 2 weeks and the medium was changed biweekly.  
On the day of the experiment, one plate was considered as a static (control) group 
while the other plate was shaking (test) plate. For the static control group, plate was 
incubated for one hour at 37°C in the Thermo Mixer with no rotation. Then, RNA was 
isolated at the end of incubation. While for the shaking test group, plate was incubated for 
45 minutes in the Thermo Mixer (Heatonly, Thermo Mixer II, Fisher Scientific) at 37°C 
under 700 rpm and the RNA was extracted after that. The experiment was done in triplicate 
for three times.    
 
Real-time quantitative PCR 
Both Ocy454-b2ARKD and Ocy454-b2ARCtrl cells were plated 1 x105 cells/ml in 6-
well plates and cultured in complete medium for 3 days at 33°C for 3 days then moved to 
a semi permissive temperature 37°C for 7-14 days. Total RNA was extracted by using the 
RNAeasy Plus Mini Kit (Qiagen, Germantown, MD, USA) according to manufacturer 
recommendations and were quantified by using NanoDrop 2000 (Thermo Fisher 
Scientific). By using 1 µg RNA, cDNA was synthesized by using qScript cDNA SuperMix 
16 
(Quana,biosciences) followed by SYBR Green (Power SYBR; Thermo Fisher Scientific) 
semi quantitative PCR (StepOnePlus; Thermo Fisher Scientific). Primer sequences are 
listed in Table 2. Gene expression between samples was calculated by using the 
comparative Ct method (-ΔΔCt), and  b-actin as reference gene and were normalized with 
control or vehicle-treated cells or by normalizing b-actin expression.  
 
 
Genes Forward sequence Reverse sequence 
Sost 5’-CTTCAGGAATGATGCCACAG 
AGGT-3’ 
5’-ATCTTTGGCGTCATAGGGAT 
GGT-3’ 
Dmp-
1 
5’-AAGCTAGCCCAGAGGGACAGG 
CAA-3’ 
5’-TTATCGGCGCCGGTCCCCG  
TAC-3’ 
b1AR 5’-TCATCGTGGTGGTGAACGTG-3’ 5’-ACCAGCAATCCCATGACCA   
G-3’ 
b2AR 5’-GGGAACGACAGCGACTTCTT-3’ 5’-GCCAGGACGATAACCGACA        
T-3’ 
Rankl 5’-GGACGGTGTTGCAGCAGAT-3’ 5’-GCAGTCTGAGTTCCAGTGG  
TA-3’ 
Table 2. RT-qPCR primer sequences used in this study 
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Statistical analysis 
 Data presented are means ± Standard Deviation (SD). Statistically significant 
differences between the control and different test groups were determined either by student 
t-test or ANOVA, depending on the number of the groups. If ANOVA test indicated a 
statistical significance, it was followed by a Bonferroni post-hoc test for pairwise 
comparisons among groups. Analyses were conducted using STATA 14.2 statistical 
software (StataCrop, College Station, TX). Alpha was set at 0.05 for rejecting the null 
hypothesis of no difference. Each experiment was conducted in triplicate and repeated 
several times, unless otherwise specified in the figure legends. 
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RESULTS 
 
Treating Ocy454 cells with norepinephrine, isoproterenol, and butoxamine 
The aim of the first experiment was to investigate the effects of bAR agonists or 
antagonists on Ocy454 cells.  The expression of different genes including: Sost, Dmp1 and 
Rankl were then evaluated. Ocy454 cells were treated with 10µM of norepinephrine, 
isoproterenol, and butoxamine for 2 hours prior to RNA isolation. Norepinephrine is the 
endogenous catecholamine that binds to both adrenergic receptors a and b. Isoproterenol 
is a chemical agent that’s usually used as a medication for bradycardia and acts as a non-
selective b adrenergic agonist. While the butoxamine is a chemical agent utilized in the 
laboratory and acts as a selective b2AR antagonist.  
mRNA expression of Sost, Rankl and Dmp1 were measured by semi quantitative 
RT-PCR for each group. Ocy454 cells showed a slight increase in the expression of Sost 
especially when treated with NE and butoxamine, however the difference between the test 
groups and the control was not statistically different (Fig 1-A). The same applies to Dmp1 
expression which shows no statistical significance between the test groups and the control 
(Figure 1-B). On the other hand, The Rankl expression increased significantly (P < 0.05) 
in the cells treated with NE and ISO, whereas butoxamine had no effect, as expected 
(Figure 1-C).  
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Figure 1: Treating Ocy454 cells with norepinephrine, isoproterenol, and butoxamine. 
mRNA expression of osteocytes-associated genes in Ocy454: A) Sost; B) Rankl and C) 
Dmp1 
   Data are expressed of relative to b Actin randomized to control 
   Data are expressed as average ± (SD) of 2 experiments, done in triplicate 
   *P < 0.05, **P < 0.01 
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Knocking down b2AR in Ocy454 
The goal of this experiment was to knock down b2AR by using shRNA. Five 
independent shRNA targeting b2AR were tested as well as 2 independent shRNA targeting 
GFP as a control group. The preliminary data showed that 2 of the shRNA-b2AR did not 
induce a reduction of b2AR (shRNA E4 and E5), therefore for the next experiment, we 
focused on the other 3  shRNA which were successful  in knocking down the b2AR 
(shRNA E6, E7 and E8) (Fig 2).  
 
 
 
Figure 2: Knocking down b2AR in Ocy454 
mRNA expression of b2AR in shRNA-GFP (Cont) and in shRNA-b2AR (Test) 
        Data are expressed of relative to b Actin randomized to control 
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b2ARKD. As expected, the b2AR expression was significantly reduced. The shRNA (E7) 
shows the most promising result regarding knocking down b2AR compared to shRNA-
GFP control group (P < 0.05) (Figure 3-A). Although it is not statistically significant, it 
was interesting to notice a slight reduction of b1AR expression especially in clone E6 and 
E8 (Figure 3–B).  For the Sost expression, a statistically significant reduction was noted in 
the shRNA-b2ARKD sub clone E6 and E8 (P < 0.05) while no change was noted in E7 
(Figure 3-C). Intriguingly, all the 3 shRNA-b2ARKD sub clones showed an increase in the 
expression of Rankl with a statistical significance in clones E6 and E8 (P < 0.05) (Figure 
3-D). Additionally, Dmp1 showed great diversity among the shRNA-b2ARKD sub clones, 
in which the E6 increased its expression dramatically (P < 0.05), E7 showed no difference, 
while the E8 showed a significant reduction in the expression (P < 0.05) (Figure 3-E).  
Since shRNA-b2AR (E7) clone showed the greatest knock down of  b2AR (more 
than 60% knock down) (Fig 3-A) and because it showed no change in Sost expression 
compared to the basal expression, we selected E7 clone as  shRNA-b2ARKD for further  
experiments. 
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Figure 3: Knocking down b2AR in Ocy454 
mRNA expression of osteocytes-associated genes in shRNA-GFP (Cont) and in shRNA-
b2AR (E6, E7, E8) A)b2AR, B)b1AR, C)Sost, D)Rankl and E)Dmp1   
  Data are expressed of relative to b Actin randomized to control 
  Data are expressed as average ± (SD) of 3 experiments, done in triplicate 
  *P < 0.05; ** P < 0.01 
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Treating shRNA-GFP and shRNA-b2ARKD with NE 
Next, we investigated whether knocking down b2AR would change the Ocy454 
response to NE treatment. In this experiment 2 groups were compared; the first group is 
shRNA-GFPcont and the other group is shRNA-b2ARKD. For each group, 2 subgroups were 
created, one as a control and the other as a test group treated with 10µM NE for 2 hours.  
 The expression of b2AR, Sost, and Rankl were measured for each subgroup. 
shRNA-GFPcont NE treated cells show a statistically significant reduction in b2AR (P < 
0.05). While the shRNA-b2ARKD NE treated cells are not showing a significant difference 
compared to its control subgroup (Fig 4-A). For the Sost expression, the shRNA-b2ARKD 
NE treated cells show a statistically significant reduction in Sost (P < 0.05), while the 
shRNA-GFPcont cells do not show any statistical significant difference (Fig 4-B). For the 
Rankl, the shRNA-b2ARKD NE treated cells show a statistical significant increase in the 
expression (P < 0.05). Surprisingly, the shRNA-GFPcont cells lost its Rankl expression 
responsiveness to NE compared to the original Ocy454 possibly due to clonal selection 
(Fig 4-C). 
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Figure 4: Treating shRNA-GFR and shRNA-b2AR with NE 
mRNA expression of osteocytes-associated genes in shRNA-GFP (Cont) and in shRNA-
b2AR (Test) A)b2AR; B)Sost and C) Rankl)   
  Data are expressed of relative to b Actin randomized to control 
  Data are expressed as average ± (SD) of 2 experiments, done in triplicate 
  *P < 0.05; ** P < 0.01 
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Fluid flow shear stress (FFSS) experiment for shRNA-GFP and shRNA-b2ARKD 
We then examined whether knocking down b2AR in osteocytes may or may not 
have an effect on osteocytes response to fluid flow shear stress. Two groups were 
compared, first group is shRNA-GFP as a control  and the other group is shRNA-b2ARKD 
as a test group. Each group were sub grouped into a static control subgroup while the other 
group is a shaking subgroup.  
The mRNA expression of Sost, Rankl and Dmp1 were measured by semi 
quantitative RT-PCR for each group. For Sost expression, shRNA-b2ARKD did not show 
any change, while shRNA-GFP showed a slight reduction in the expression after shaking 
although the difference was not statistically significant (Figure 5-A). On the other hand, 
the Rankl expression showed a statistically significant increase in the expression after 
shaking in both shRNA-GFP and shRNA-b2ARKD cell groups (P < 0.01) (Figure 5-B). In 
addition, the expression of Dmp1 was significantly elevated in both groups after shaking 
(P < 0.01) (Figure 5-C). 
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Figure 5: Fluid flow shear stress shRNA-GFR and shRNA-b2AR 
mRNA expression of osteocytes-associated genes in shRNA-GFP (Cont) and in shRNA-
b2AR (Test) in static and shaking modes A)Sost; B)Rankl and C) Dmp1   
  Data are expressed of relative to b Actin randomized to control 
  Data are expressed as average ± (SD) of 3 experiments, done in triplicate 
  *P < 0.05; ** P < 0.01  
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DISCUSION 
 
It has been known in the last decade that osteocytes are orchestrators for both 
osteoblasts and osteoclasts activity in response to mechanical stimuli (Robling, Niziolek et 
al. 2008, Nakashima, Hayashi et al. 2011) and hormonal cues. However, several aspects of 
osteocyte’s function and regulation are still not well understood. One of these aspects is 
the influence of the sympathetic nervous system (SNS) on osteocytes.  In spite of the fact 
that several studies reported that SNS influences the bone mass by regulating local bone 
remodeling (Nagao, Feinstein et al. 2011), the exact mechanism of this influence remains 
unknown. Moreover, the role of b2AR in osteocytes has not been studied (Elefteriou 2018).   
In an attempt to understand the link between SNS and bone remodeling, the main objective 
of this work was to study -for the first time to our knowledge- the role of beta 2 adrenergic 
receptor  (b2AR) in osteocytes. 
To investigate that, we used the newly introduced osteocyte-like cell line Ocy454. 
Ocy454 has the advantage of high expression of Sost and is able to respond to hormonal 
and mechanical stimuli resembling the physiological role of osteocytes in vivo. To 
knockdown the receptor of interest (b2AR), short hairpin RNA technique was used. The 
knockdown was confirmed by mRNA expression of b2AR by using semi quantitative RT-
PCR.  
The first experiment was performed to obtain a baseline response of Ocy454 toward 
different agents which have an agonistic or antagonistic effect of bAR. Cells were treated 
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with norepinephrine, isoproterenol, and butoxamine. The results show that mRNA 
expression of Sost did not change after treatment with the three agents. On the other hand, 
Rankl showed a high upregulation after treating Ocy454 with NE and ISO. Interestingly, a 
similar upregulation response of an osteoblast-like cell line to NE and ISO has been 
reported previously (Elefteriou 2018). It has been shown that NE and ISO induce bone 
turnover by stimulating osteoclastogenesis by upregulating a pro-osteoclastogenic cytokine 
Rankl (Elefteriou, Ahn et al. 2005, Elefteriou 2018). This could suggest a similar effect of 
osteocyte-derived Rankl. Studies have reported that osteocyte-derived Rankl plays a crucial 
role in bone remodeling and bone loss associated with unloading (Xiong, Onal et al. 2011). 
Furthermore, Rankl was the first b2AR target gene recognized in osteoblasts. In view of 
the abovementioned facts, it can be hypothesized that, in vivo, the sympathetic nervous 
system, by releasing NE, controls bone remodeling through action on osteocytes, which 
express b2AR  (Asada, Katayama et al. 2013).  
 Several experiments were done on different shRNA-b2AR to select the  most 
successful clone in knocking down b2AR, which was clone (E7). This specific clone was 
able to knockdown b2AR by more than 60% (Fig 2) with preserving a comparable Sost 
expression to that expressed by control cells. For this reason, shRNA-b2AR (E7) was 
chosen for the afterward experiments. To assess successful knock-down of the receptor, 
control and the KD cells were treated with NE. Interestingly, the results showed the KD 
group increased the expression of Rankl significantly in response to NE treatment (Figure 
4-C) suggesting that the remaining receptors were still able to induce a full response to NE. 
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 The (FFSS) experiment was done to evaluate whether b2AR expression was needed 
for a full osteocytes response to mechanical forces. The results show that both groups did 
not change Sost expression significantly and that both groups increased Dmp1 equally. On 
the other hand, although both groups significantly increased the expression of Rankl after 
shaking, the control group elevated the Rankl expression by 1.5 fold while the KD group 
only increased it by 0.5 fold which is statistically significant between the two shaking 
subgroups. These preliminary data show that Sost is not dependent on b2AR while Rankl 
expression is affected by b2AR level. This could suggest that b2AR has a role in 
controlling Rankl expression in osteocytes. Hence, this conclusion also strengthens the idea 
that SNS might induce bone loss through Rankl mediated osteoclastogenesis promoted by 
osteocytes.  
One of the limitations of this study is related to the method of silencing the gene. 
Short hairpin RNA is a gene reduction method that is not able to eliminate a specific gene 
completely. Although it is a good gene knocking down method, the remaining receptors 
could be able to generate a full response. Also, it was noticed that the control group 
(shRNA-GFP) did not behave as the original Ocy454 cell line (Fig 4-C), additional shRNA 
control clone that is more reflective of Ocy454 cell line is needed for future studies. At the 
time of this experiment, a more advanced gene silencing tool like CRISPR/Cas9 was not 
readily available. Future studies are required to knock-out completely the b2AR. One of 
the suitable candidate tool to achieve that is CRISPR/Cas9. CRISPR-Cas system utilizes 
both proteins and short RNAs to target specific DNA sequences for cleavage which allow 
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a better knocking out result compared with the other available tools (Hsu, Lander et al. 
2014). 
The other limitation is an intrinsic restriction of the Ocy454 cell line. In spite of the 
fact that Ocy454 has the benefit of high expression of Sost/Sclerostin and are able to 
respond to cytokine (PGE2), hormonal (PTH) and mechanical stimuli (Spatz, Wein et al. 
2015), it has some shortcomings. Ocy454 is a laboratory produced osteocytic-like cell 
which might not fully recapitulate the in vivo osteocytes. Additionally, Ocy454 cell line is 
a heterogeneous population with different stages of differentiation which in turn might 
affect the mRNA gene expression (Shi, Uda et al. 2018). Therefore, future studies should 
utilize a homogenous osteocytes-like cell line. The experiment can be done by using a 
clonal cell line of Ocy454 like the newly established clonal cell line reported by our group, 
Ocy454-12H (Shi, Uda et al. 2018). 
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CONCLUSIONS 
 
This work has shown that, osteocytes do express b2AR and that b1AR and b2AR 
are almost equally expressed in osteocytes. Secondly, we have demonstrated that upon 
treatment of Ocy454 with norepinephrine and isoproterenol, there is a significant 
upregulation of Rankl, whereas Sost has not been regulated. Lastly, preliminary data show 
that b2AR is possibly involved in osteocyte’s mechanosensation.  
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